• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
LeadershipMartin Shkreli

Yet Another Reason to Hate Martin Shkreli

By
Daniel Roberts
Daniel Roberts
Down Arrow Button Icon
By
Daniel Roberts
Daniel Roberts
Down Arrow Button Icon
December 16, 2015, 5:25 PM ET

Martin Shkreli is raising eyebrows again.

Since jacking up the price of HIV medication Daraprim by more than 5,000% in September, the young hedge fund manager and pharmaceutical executive has become a household name and drawn the ire of Democratic Presidential contenders Hillary Clinton and Bernie Sanders.

More recently, Shkreli made headlines when a Businessweek story revealed that he paid $2 million for the only known copy of a Wu-Tang Clan album.

In an exclusive interview with the Web site HipHopDX on Wednesday, Shkreli sounds off on everything from his business practices to Wu-Tang to Taylor Swift. Some of the things he says are downright shocking. They aren’t statements a CEO, no matter how bold or careless, would usually say on the record.

So it begs the questions: Is this acceptable? Should investors take action?

In the HipHopDX interview, Shkreli discusses the recent comments from Wu-Tang Clan members who say they wish they could take their album back. “If I hand you $2 million, f—ing show me some respect,” he said. “At least have the decency to say nothing or ‘no comment.’”

If anyone wants to hear his Wu-Tang Clan album, of which there is only one copy, he has a price for that, too. “I’m not going to play it for no reason,” he said. “If Taylor Swift wants to come over and s— my d— I’ll play it for her.”

 

Shkreli and Turing Pharmaceuticals, the firm he leads, did not respond to a request for comment.

“The bottom line is, when you look at his choice of language and the way he describes himself and others, it’s very hard to understand how this person is the chief executive officer of a company,” says Lauren Rikleen, an attorney, author, and president of the Rikleen Institute for Strategic Leadership. “A CEO who is completely uninterested in the impact of his words is bad for business.”

Rikleen, who has often written about gender issues in business, adds that Shkreli’s comment about Taylor Swift should be especially troubling to his business partners. “His disdain for women comes through in that comment,” she says. “You don’t make that kind of comment unless you have a complete antipathy towards women, you just don’t, you wouldn’t think of saying it. So, at what point do his investors say, ‘Is this who I trust to run this business?’ That’s the question that should be asked amidst all this publicity he’s getting.”

Shkreli has shown that he isn’t bothered by any hate sent his way on social media. He proudly tweeted the HipHopDX story, with one of his own quotes from the article.

“If I hand you $2 million, fucking show me some respect. At least have the decency to say nothing or ‘no comment.’”https://t.co/yr4UVdMDxe

— Martin Shkreli (e/acc) (@MartinShkreli) December 16, 2015

In some ways, Shkreli’s attitude mirrors that of presidential candidate Donald Trump. He embraces critics and responds to some of them on Twitter, usually dismissively. Rikleen notes the similarities, and says that as far as Trump goes: “I blame the media here more than anything. They give him whatever air time he wants because he’ll say things that drive ratings.”

Is the media also to blame for making Shkreli famous? With every new, shocking thing he does, every outlet covers it. (Fortune, too, is doing so.) If the press ignores his antics, will he go away?

The better question may be whether anyone involved in Shkreli’s businesses will decide he needs to go away.

Turing Pharmaceuticals is a private company and can happily do as it wishes in terms of maneuvering prices for profit. But will Shkreli’s cavalier remarks be tolerated by his partners? Meanwhile, it isn’t clear who those partners are. Privco, the financial intelligence firm, was unable to find any information at all on Turing’s shareholders or investors. “The company seems to be extremely secretive,” a Privco analyst tells Fortune.

Shkreli started hedge fund MSMB Capital in his 20s. In 2011 he started a pharma called Retrophin (RTRX), which repeatedly raised the prices of old drugs. The company fired him last year and has accused him, in federal court in Manhattan, of taking money from Retrophin’s coffers to pay back investors in MSMB Capital. Shkreli called the claims “preposterous.”

[fortune-brightcove videoid=4592160380001]

About the Author
By Daniel Roberts
See full bioRight Arrow Button Icon

Latest in Leadership

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Most Popular

placeholder alt text
Economy
Trump may have shot himself in the foot at the Fed, as Powell could stay on while Miran resigns from White House post
By Eleanor PringleFebruary 4, 2026
1 day ago
placeholder alt text
Investing
Tech stocks go into free fall as it dawns on traders that AI has the ability to cut revenues across the board
By Jim EdwardsFebruary 4, 2026
1 day ago
placeholder alt text
Politics
Peter Thiel warns the Antichrist and apocalypse are linked to the ‘end of modernity’ currently happening—and cites Greta Thunberg as a driving example
By Nick LichtenbergFebruary 4, 2026
20 hours ago
placeholder alt text
Success
After decades in the music industry, Pharrell Williams admits he never stops working: ‘If you do what you love everyday, you’ll get paid for free'
By Emma BurleighFebruary 3, 2026
2 days ago
placeholder alt text
Success
In 2026, many employers are ditching merit-based pay bumps in favor of ‘peanut butter raises’
By Emma BurleighFebruary 2, 2026
3 days ago
placeholder alt text
North America
Gates Foundation doubles down on foreign aid as U.S. government largely withdraws
By Thalia Beaty and The Associated PressFebruary 3, 2026
2 days ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Latest in Leadership

grace
CommentaryRobotics
I’m a 25-year-old founder who loves robots but too many humanoids are militant and creepy-looking. Things need to change—just look at Elon Musk
By Grace BrownFebruary 5, 2026
2 hours ago
lewis
Big Techbooks
Michael Lewis reveals he’s got a deal to write the Sam Altman book—when ChatGPT is ready to write a rival draft
By Nick LichtenbergFebruary 5, 2026
2 hours ago
Photo of OpenAI CEO of Applications Fidji Simo.
AIOpenAI
OpenAI announces Frontier, an AI agent platform for enterprises to power apps like Salesforce and Workday—but could it eventually replace them?
By Sharon GoldmanFebruary 5, 2026
2 hours ago
sam wolf
Commentaryactivist investing
Activist investors are more dangerous to CEOs than ever. Here are 3 ways to safeguard your leadership
By Sam WolfFebruary 5, 2026
3 hours ago
paul weiss
LawJeffrey Epstein
Epstein’s fondness for elite lawyer ends in downfall
By Tom Schoenberg and BloombergFebruary 5, 2026
3 hours ago
karp
LawJeffrey Epstein
Karp steps down as Paul Weiss chairman after Epstein emails
By Meghan Tribe, Tatyana Monnay and BloombergFebruary 5, 2026
3 hours ago